-
Well-known pharmaceutical companies were fined 2.65 million!
Time of Update: 2021-08-11
The "Visible Foreign Body" item under the item [inspection] of the batch of drugs does not meet the requirements of the 2015 edition of the Chinese Pharmacopoeia (inspection report number: YC202001911) o According to Article 98 Paragraph 3 of the "Drug Administration Law of the People's Republic of China" According to the provisions of item (7) "In any of the following circumstances, the drugs are inferior: (7) Other drugs that do not meet the drug standards .
-
Strictly check pharmacies and Chinese medicine doctors in one place
Time of Update: 2021-08-11
4. Severely crack down on the illegal activities of pharmaceutical retail companies that use medical devices or drugs in the name of "free inspection", "experience" and "trial" to carry out diagnosis and treatment activities without authorization .
-
Cinda's PD-1 first-line advanced liver cancer indication approved
Time of Update: 2021-08-11
7); Compared with the sorafenib group, the independent imaging review committee (IRRC) assessed the progress-free survival of the Sintilimab-bevacizumab biosimilar group It also improved significantly (median 4.
-
All Arrows: Progress in Arrow RNAi Drugs
Time of Update: 2021-08-11
Arrow today announced that its RNAi therapy ARO-HSD targeting HSD17B13 has shown certain early effects in a phase I clinical trial involving 5 NASH patients (the rest are healthy volunteers) .
-
Negotiation drugs need more "dual channels"
Time of Update: 2021-08-11
Negotiation drugs trapped in the "last mile"Let the policy temperature reach the pain points of patientsOn June 18, the National Medical Insurance Administration released the second batch of negotiated drug allocation institutions, covering 84,000 designated medical institutions across the country, and correspondingly equipped 92 medical insurance drugs .
-
Lifang Pharmaceutical Subsidiary Itraconazole Oral Liquid Received Drug Registration Acceptance Notice
Time of Update: 2021-08-11
On the 28th, Lifang Pharmaceutical announced that Hefei Chengzhi Biopharmaceuticals, a wholly-owned subsidiary, received the "Notice of Acceptance" for the production registration of itraconazole oral liquid issued by the State Food and Drug Administration .
Treatment of oral and/or esophageal candidiasis in patients with HIV positive or immune system damage .
-
FDA requires Pfizer/BioNTech and Moderna new crown vaccines to add label warnings
Time of Update: 2021-08-11
However, on June 24, according to foreign media reports, American experts concluded that there is a "possible link" between rare cases of cardiac inflammation and mRNA vaccines, which has brought certain harm to Pfizer/BioNTech and Moderna's vaccine injections.
-
The fifth batch of national sourcing 251 products are planned to be selected!
Time of Update: 2021-08-11
Medical Network News, June 24, after a whole day of intense and fierce confrontation, on the evening of June 23, Shanghai Sunshine Pharmaceutical Purchasing Network "overtime" announced overnight the results of the fifth batch of 62 nationally sourced varieties of the proposed selection.
-
National Health Commission: Increase the village doctor’s basic medicine subsidy, and it is strictly forbidden to withhold or deduct in the name of assessment
Time of Update: 2021-08-11
For government-run community health service centers (stations) and township health centers, the transfer payment funds are mainly used to make up for the subsidy of the current income and expenditure difference after the approved income and expenditure, and to promote the comprehensive reform of primary medical and health institutions.
-
Hisun Pharmaceutical's micafungin sodium for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-08-11
The company's 2020 sales revenue of micafungin sodium for injection is approximately 39.
33 million yuan, and the sales revenue from January to March 2021 is approximately 12.
-
BeiGene anti-PD-1 antibody approved for two new indications
Time of Update: 2021-08-11
According to a press release issued by BeiGene, the indications for these two sDNAs are: combined chemotherapy for the treatment of patients with first-line advanced non-squamous non-small cell lung cancer (NSCLC), and treatment of unresectable livers that have received previous treatment.
-
Buying medicine online can get medical insurance
Time of Update: 2021-08-11
On June 12, the Guangzhou Municipal Medical Insurance Bureau announced that during the new crown epidemic, employees in the city can use the "Suikang" applet to purchase over-the-counter drugs that meet the payment scope of the city’s medical insurance personal account at designated retail pharmacies.
-
Shanghai and Beijing become the most competitive pharmaceutical industry centers in the Asia-Pacific region
Time of Update: 2021-08-11
In the Beijing market, CB Richard Ellis found that active investments in the life sciences industry have brought demands for corporate tenants to upgrade office space, and business parks are preferred for the expansion of local pharmaceutical companies .
-
The State Food and Drug Administration revised the instructions for Oxiracetam preparations and somatostatin for injection
Time of Update: 2021-08-11
On the 24th, the State Food and Drug Administration issued an announcement on revising the instructions for Oxiracetam preparations .
The holder of the drug marketing authorization shall replace the instructions and labels of the drugs that have been shipped out of the factory within 9 months after filing .
-
JAK inhibitor is blocked again!
Time of Update: 2021-08-10
Pfizer's JAK inhibitor Xeljanz, in a post-marketing study for patients with rheumatoid arthritis, discovered dangerous cardiac side effects and additional risks of cancer, which caused the FDA to raise safety concerns about JAK inhibitor drugs .
-
Simcere introduces 2 Alzheimer's disease drug candidates
Time of Update: 2021-08-10
They are the N3pE-targeted oral small molecule glutamyl peptide cyclotransferase in clinical phase 2b ( QPCT) inhibitor varoglutamstat (PQ912), and the monoclonal N3pE antibody PBD-C06 in the preclinical research stage .
-
GSK China's pharmaceutical business license cancellation high-value business spin-off MNC "slimming" tide is coming?
Time of Update: 2021-08-10
Following Bristol-Myers Squibb, GlaxoSmithKline (GSK) also announced the cancellation of the drug business license of its subsidiary in China .
8 billion to raise funds for the acquisition of TESARO project investment; secondly, GSK and Pfizer will merge their consumer healthcare businesses Establish a joint venture company .
-
How to divide the “ten billion cake” of the fourth domestically-made bevacizumab biosimilar drug approved?
Time of Update: 2021-08-10
On June 22, Hengrui Medicine's bevacizumab biosimilar was approved in China for the indications of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer .
-
National Food and Drug Administration: Transcatheter aortic valve system approved for marketing
Time of Update: 2021-08-10
National Machinery Note 20203130445 80 Cardiovascular optical coherence tomography equipment and accessories Shenzhen Zhongke Microlight Medical Device Technology Co.
National Machinery Note 20203130445 80 Cardiovascular optical coherence tomography equipment and accessories Shenzhen Zhongke Microlight Medical Device Technology Co.
-
Roche's new intraocular drug delivery system ranibizumab PDS enters priority review in the United States
Time of Update: 2021-08-10
If approved, PDS will be the first and only intraocular implant that can deliver drugs continuously, and will provide an alternative to frequent intraocular injections of anti-vascularity for patients with wet AMD The treatment of endothelial growth factor (VEGF), which is currently the standard care plan for wet AMD .
